<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03609528</url>
  </required_header>
  <id_info>
    <org_study_id>CamPROBE</org_study_id>
    <nct_id>NCT03609528</nct_id>
  </id_info>
  <brief_title>CamPROBE: Developing a Safer and Simple Device for Local Anaesthetic Transperineal Prostate Biopsies</brief_title>
  <acronym>CamPROBE</acronym>
  <official_title>CamPROBE: Developing a Safer and Simple Device for Local Anaesthetic Transperineal Prostate Biopsies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CamPROBE study investigates the rate of infective complications using the Cambridge&#xD;
      Prostate Biopsy Device method of local anaesthetic transperineal prostate biopsies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current method for diagnosing prostate cancer requires a biopsy needle to pass through&#xD;
      the bowel wall to reach the prostate. Bacteria in the bowel inevitably enter the urinary&#xD;
      system and blood stream. A significant number of men develop infections despite preventative&#xD;
      antibiotics (1 in 10 develop fevers/shivers and 1-2 in 100 get a life-threatening infection).&#xD;
      It is crucial we find a safer biopsy method for suspected prostate cancer as over 1 million&#xD;
      rectal biopsies occur each year.&#xD;
&#xD;
      A safer alternative device was developed, performed under local anaesthetic using the&#xD;
      transperineal route: CamPROBE (Cambridge Prostate Biopsy Device). CamPROBE biopsies are taken&#xD;
      through the perineum (the area under the testicles), so there is no infection risk, and it's&#xD;
      just as good at diagnosing prostate cancer. This investigation progresses from a prototype to&#xD;
      a disposable, single use device that any UK hospital can use. The study will assess&#xD;
      CamPROBE's ability to reduce infections from prostate biopsies and its usability as an&#xD;
      alternative to the current standard biopsies.&#xD;
&#xD;
      Men recommended to undergo a prostate biopsy will be eligible for this multi-centre study.&#xD;
      For each patient, the study will take approximately 30 days, consisting of: recruitment, 1&#xD;
      day for the procedure (replaces the standard biopsy pathway) and questionnaires on day 1, 7&#xD;
      and 30. This timeframe will not introduce delays in the patients' normal standard care&#xD;
      pathway. Patients will have a transperineal biopsy with CamPROBE instead of the current&#xD;
      transrectal method. Biopsy samples will be treated the same as standard procedure. Patients'&#xD;
      acceptability of the procedure and complications will be measured using patient self-reported&#xD;
      questionnaires.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2019</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">October 2, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Infection</measure>
    <time_frame>30 days post biopsy</time_frame>
    <description>Changes in incidence of infection as measured using patient self-reported Follow-Up Questionnaires and telephone assessments.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient reported pain score</measure>
    <time_frame>30 days post biopsy</time_frame>
    <description>Patient reported pain scores as measured using patient self-reported questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological functions post biopsy</measure>
    <time_frame>30 days post biopsy</time_frame>
    <description>Patient biological functions as measured using patient self-reported questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient willingness to have a repeat biopsy</measure>
    <time_frame>30 days post biopsy</time_frame>
    <description>Patients' willingness to have a repeat biopsy as measured using patient self-reported questionnaires</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinician Perception</measure>
    <time_frame>1 day</time_frame>
    <description>Clinician perception of the device and the performance of the CamPROBE assessed using Clinical Performance Assessment questionnaire</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>CamPROBE biopsy method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be completed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CamPROBE</intervention_name>
    <description>To be completed</description>
    <arm_group_label>CamPROBE biopsy method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in the clinical investigation the participant must:&#xD;
&#xD;
          -  Have given written informed consent to participate&#xD;
&#xD;
          -  Be aged 18 years and over&#xD;
&#xD;
          -  Be suitable for a prostate biopsy and clinically due to have a biopsy for diagnostic&#xD;
             or surveillance purposes&#xD;
&#xD;
          -  Be willing and able to comply with scheduled visits and completion of study&#xD;
             questionnaires&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The presence of any of the following will preclude participant inclusion:&#xD;
&#xD;
          -  Contraindication to a prostate biopsy&#xD;
&#xD;
          -  Previous perineal or anal surgery&#xD;
&#xD;
          -  Unable to lie down with legs in a stirrup for at least 45 minutes, as assessed by a&#xD;
             clinician&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 1, 2018</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Vincent Gnanapragasam</investigator_full_name>
    <investigator_title>Mr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>October 25, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

